Long-term peritoneal dialysis (PD) may lead to peritoneal fibrosis and ultrafiltration failure. The latter occurs due to high solute transport rates and diabetiform peritoneal sclerosis. Angiotensin-II (AII) is known to be a growth factor in the development of fibrosis and a number of animal studies have shown it likely that inhibiting the effects of AII by angiotensin-converting enzyme (ACE) or angiotensin receptor blocker (ARB) will attenuate these complications.
Objective
To investigate the effects of ACE/AII inhibitors in long-term PD patients.
Patients and Setting
We analyzed data from 66 patients treated with PD therapy at our center for at least 2 years, during which time at least 2 standard peritoneal permeability analyses (SPAs) were performed. 36 patients were treated with ACE/AII inhibitors (ACE/ARB group); the other 30 received none of the above drugs during the entire follow-up (control group). The two groups were compared with respect to changes in peritoneal transport over the follow-up time.
Results
A significant difference in time course of peritoneal transport was found between the 2 groups: in the ACE/ARB group, small solute transport had decreased, while it had increased in the control group. This finding was confirmed by analysis using mixed model for repeated measures. The value of mass transfer area coefficient of creatinine was influenced by the duration of PD therapy (p = 0.017) and this interaction was different with respect to use of ACE/AII inhibitors (p = 0.037). The trend was not found in protein clearances or fluid kinetics.
Conclusion
Our findings suggest that ACE/AII inhibition is likely to prevent the increase in mass transfer area coefficients that occurs in long-term PD, which is in line with results of experimental animal studies.
TermorshuizenF., KorevaarJ.C., DekkerF.W., van ManenJ.G., BoeschotenE.W., KredietR.T.; The Netherlands Cooperative Study on Adequacy of Dialysis Group. Hemodialysis and peritoneal dialysis: a comparison of adjusted mortality rates by the duration of dialysis: analysis of the Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD) 2.J Am Soc Nephrol2003; 14: 2851–60.
2.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
3.
HondaK., NittaK., HoritaH., YumuraW., NiheiH.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.Nephron1996; 72: 171–6.
4.
MateijsenM.A.M., van der WalA.C., HendriksPMEM, ZweersM.M., MulderJ., StruijkD.G.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.Perit Dial Int1999; 19: 517–25.
CombetS., MiyataT., MoulinP., PouthierD., GoffinE., DevuystO.Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis.J Am Soc Nephrol2000; 11: 717–28.
7.
De VrieseA.S., TiltonR.G., StephanC.C., LameireN.Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane.J Am Soc Nephrol2001; 12: 1734–41.
8.
SzetoC.C., ChowK.M., PoonP., SzetoC.Y.K., WongT.Y.H., LiP.K.T.Genetic polymorphism of VEGF: impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients.Kidney Int2004; 65: 1947–55.
9.
ZweersM.M., de WaartD.R., SmitW., StruijkD.G., KredietR.T.The growth factors VEGF and TGF-beta1 in peritoneal dialysis.J Lab Clin Med1999; 134: 124–32.
10.
KangD.H., HongY.S., LinH.J., ChoiJ.H., HanD.S., YoonK.I.High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation.Perit Dial Int1999; 19: 221–30.
11.
MargettsP.I., KolbM., HoffC.M., YuL., HoffC.M., GauldieJ.A chronic inflammatory infusion model of peritoneal dialysis in rats.Perit Dial Int2001; 21(Suppl 3): S368–72.
12.
MargettsP.I., KolbM., GaltT., HoffC.M., ShockleyT.R., GauldieJ.Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function.J Am Soc Nephrol2001; 12: 2029–39.
13.
WongT.Y.H., PhillipsA.O., WitowskiJ., TopleyN.Glucose-mediated induction of TGFβ1- and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent.Kidney Int2003; 63: 1404–16.
14.
WolfG., NeilsonE.G.Angiotensin-II as a renal growth factor.J Am Soc Nephrol1993; 3: 1531–40.
KagamiS., BorderW.A., MillerD.E., NobleN.A.Angiotensin-II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.J Clin Invest1994; 93: 2431–7.
17.
BrennerB.M., CooperM.E., de ZeeuwD., KeaneW.F., MitchW.E., ParvingH.H.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med2001; 345: 861–9.
18.
LewisE., HunsickerL., BainR., RhodeR.The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy [Erratum published in N Engl J Med 1993; 330: 152].N Engl J Med1993; 329: 1456–62.
19.
LewisE., HunsickerL., ClarkeW.R., BerlT., PohlM.A., LewisJ.B.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med2001; 345: 851–60.
20.
LiP.K.T., ChowK.M., WongT.Y.H., LeungC.B., SzetoC.C.Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis.Ann Intern Med2003; 139: 105–12.
van WestrhenenR., DragtC.A.M., KunneC., ZweersM.M., KredietR.T.Lisinopril protects against the development of fibrosis during chronic peritoneal exposure to dialysis fluid [Abstract].Perit Dial Int2004; 24(Suppl 2): S10.
23.
VandenbrouckeJ.P.When are observational studies as credible as randomised trials?Lancet2004; 22(363): 1728–31.
24.
PannekeetM.M., ImholzA.L., StruijkD.G., KoomenG.C., LangedijkM.J., SchoutenN.The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients.Kidney Int1995; 48: 866–75.
25.
SmitW., van DijkP., LangedijkM.J., SchoutenN., StruijkD.G.Peritoneal function and assessment of reference values using a 3.86% glucose solution.Perit Dial Int2003; 23: 440–9.
26.
KredietR.T., StruijkD.G., KoomenG.C., AriszL.Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70.ASAIO Trans1991; 37: 662–7.
27.
WaniewskiJ., HeimburgerO., WerynskiA., LindholmB.Aqueous solute concentrations and evaluation of mass transport coefficients in peritoneal dialysis.Nephrol Dial Transplant1992; 7: 50–6.
28.
WaniewskiJ., WerynskiA., HeimburgerO., LindholmB.Simple membrane models for peritoneal dialysis. Evaluation of diffusive and convective solute transport.ASAIO J1992; 38: 788–96.
29.
SmitW., StruijkD.G., Ho-dac-PannekeetM.M., KredietR.T.Quantification of free water transport in peritoneal dialysis.Kidney Int2004; 66: 849–54.
30.
ZweersM.M., ImholzA.L., StruijkD.G., KredietR.T.Correction of sodium sieving for diffusion from the circulation.Adv Perit Dial1999; 15: 65–72.
31.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
32.
DumanS., Wieczorowska-TobisK., StyszynskiA., KwiatkowskaB., BreborowiczA., OreopoulosD.G.Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.Adv Perit Dial2004; 20: 31–6.
33.
CoronelF., HortalL., NaranjoP., CruceyraA., BarrientosA.Captopril, proteinuria and peritoneal protein leakage in diabetic patients.Nephron1989; 51: 443.
34.
CoronelF., BerniA., CigarranS., CalvoN., HerreroJ.A.Effects of angiotensin-II receptor blocker (irbesartan) on peritoneal membrane functions.Adv Perit Dial2004; 20: 27–30.
35.
FavazzaA., MontanaroD., MessaP., AntonucciF., GropuzzoM., MioniG.Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine.Perit Dial Int1992; 12: 287–91.
36.
RipleyE.B., GehrT.W., KishC.W., SicaD.A.Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition.Perit Dial Int1994; 14: 378–83.
37.
Rojas-CamposE., Cortes-SanabriaL., Martinez-RamirezH.R., GonzalezL., Martin-del-CampoF., Gonzalez-OrtizM.Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients.Perit Dial Int2005; 25: 576–82.
38.
DaviesS.J., BryanJ., PhilipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
39.
ParikovaA., SmitW., StruijkD.G., ZweersM.M., KredietR.T.The contribution of free water transport and small pore transport to the total fluid removal in peritoneal dialysis.Kidney Int2005; 68: 1849–56.
